Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual ...
Clobetasol is a powerful steroid approved for reducing inflammation and pain following the approximately seven million ocular surgeries performed annually in the U.S. In August 2023, Eyenovia secured ...
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombiâ„¢ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for ...